Trial of Solanezumab in Preclinical Alzheimer's Disease.

ABSTRACT:

Background

Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer's disease have had mixed results.

Methods

We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer's disease. Persons 65 to 85 years of age with a global Clinical Dementia Rating score of 0 (range, 0 to 3, with 0 indicating no cognitive impairment and 3 severe dementia), a score on the Mini-Mental State Examination of 25 or more (range, 0 to 30, with lower scores indicating poorer cognition), and elevated brain amyloid levels on ¹⁸F-florbetapir positron-emission tomography (PET) were enrolled. Participants were randomly assigned in a 1:1 ratio to receive solanezumab at a dose of up to 1600 m

SUBMITTER: Sperling RA 

PROVIDER: S-EPMC10559996 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature